MoonRISe-1: Evaluating the Promise of TAR-210 for Intermediate-Risk NMIBC

At the 2024 AUA Annual Meeting, Roger Li, MD, of Moffitt Cancer Center, provides commentary on the rationale, design, and potential impact of the MoonRISe-1 study, which focuses TAR-210—a drug-eluting stent that delivers erdafitinib directly to the bladder—for intermediate-risk NMIBC.

Dr. Li explains covers eligibility criteria, use of urinary ctDNA for detecting FGFR alterations, and the promise of TAR-210 to provide an effective, low-toxicity treatment options for these patients.